7Baggers

yjaplomb  
34â—‰
Member since: 2021-01-24
Followers: n/a
Following: n/a
Posts: 11
Replies: 1

This person is pretty lazy
Stocks
SOS - great opportunity for short squeeze
By: 
👤 yjaplomblazy guy 
đź’¬ 11
   Mar 01, 2021

$sos - has been severely manipulated and damaged by false allegations of Hidenberg Research Twitter regarding lack of existence of SOS headquarter building in China, and lifting of mining equipments off another company’s website along with a few other allegations regarding similarities of website fonts to its subsidiary. Based on these insufficient evidences, Hidenberg Research destroyed SOS shareholders’ values last week by claiming that it thinks $SOS has scammed $198 million from investors.

However, all evidence seem to point to legitimacy and existence of $SOS headquarter behind the hotel that Hidenberg allegedly visited. Also, underwriters for the $198 mil. gross proceeds include Morgan Stanley and Credit Suisse, their reputations are also on the line. It would be very odd the none of the major investors would examine mining rigs before investing significant sum of their money. It is irresponsible, unethical, and sad how short sellers like Hidenberg Research can sacrifice shareholders’ interests to unjustly enrich themselves without feeling guilty...


Reply
Aphria arbitrage opportunity from Tilray merger
By: 
👤 yjaplomblazy guy 
đź’¬ 11
   Feb 12, 2021

$apha - APHA will pop if merger with TLRY goes through. Aphria shareholders will receive 0.8381 Tilray shares for each Aphria share they own.

TLRY currently trades at $34.36. 0.8381 * $34.36 = $28.80. Currently, APHA trades at $18.63. If their merger do happen, one may benefit from the arbitrage opportunity here by simply buying APHA shares.


Reply
Genfit SA - a 15 bagger in the making
By: 
👤 yjaplomblazy guy 
đź’¬ 11
   Feb 10, 2021

$gnft - phase 2 trial data support its product elafibranor as novel treatment for Primary Biliary Cholangitis (“PBC”) - a chronic liver disease resulted from the destruction of intrahepatic bile duct. This qualifies $gnft to proceed to pivotal Phase 3 trial.

FDA granted elafibranor Breakthrough Therapy Designation, based on its impressive Phase 2 data.

Genfit is trying to bring Elafibranor, to market in several indications including Non-Alcoholic Steatohepatitis (“NASH”) and PBC. Studies estimate that 3-12% of the US population has NASH, indicating that up to 40 M of population may have NASH.

Furthermore, the prevalence percentage is expected to increase due to expected higher obesity population. The total market size is expected to increase significantly. The estimated market size will be between $20 - $35 billion by 2030. $gnft also partnered with LabCorp in marketing diagnostic tests NIS4.

Phase II results in PBC were promising and showed much greater effectiveness than Intercept’s Ocaliva. The market size of PBC is expected to grow from $562 M. in 2017 to $9 Bil. in 2026. The most conservative valuation would place $gnft at a market cap of $3 Bil., which equates to share price of around $75 - a 15x of current share price.


Reply
Iterum Therapeutics
By: 
👤 yjaplomblazy guy 
đź’¬ 11
   Feb 09, 2021

$itrm - The company focuses on developing antibiotics combatting drug-resistant pathogens for life-threatening diseases. The company's main product Sulopenem has been accepted by FDA for review in treating urinary tract infection (“UTI”).

In the U.S. there is approximately 25 million infections on annual basis, and the multi-drug resistance in UTI is growing rapidly. The overall addressable market is estimated to be over $25 billion, and this will be humongous revenue growth for $itrm. Upon FDA approval, $itrm may surge past $5.


Reply
Vaxart Inc. - Beast will fight back with vengeance
By: 
👤 yjaplomblazy guy 
đź’¬ 11
   Feb 08, 2021

$vxrt - stock dropped over 65% last week after Phase 1 COVID-19 oral vaccine result as participants showed lack of antibodies.

What most of people failed to realize was that the study passed both safety and immunogenicity thresholds.

Furthermore, VXA-CoV2-1 induced potent CD8+ T-cell responses and is likely effective against new and emerging COVID-19 variant strains.

It clearly succeeded in its phase 1 trial, and is on its way into phase 2. $vxrt oral vaccine if succeeded will be the first oral vaccine against COVID-19. This likely will generate monster demands for this small biotech, and stocks can easily take off to $100/share of it succeeds in its development of oral vaccine for COVID-19.


Reply
Purple Biotech - a multibagger in the making
By: 
👤 yjaplomblazy guy 
đź’¬ 11
   Feb 07, 2021

$sava - this one has been absolutely amazing. I first bought $sava at around $7. This one went over to $117 last week, but dropped to current price of $44.80.

The surge was due to Cassava Sciences' Alzheimer's drug Simufilam, which has consistently shown to be safe and effective. Of course, then you have bears came soon after stating it is too soon to make the call that Sumufilam is effective at all or mere a placebo effect.

However, the fact is Simufilam with more than a decade of consistent data, has consistently shown to be safe and effective against Alzheimer’s Disease, And the fact that many people are urgently in need of help. I expect Simufilam to have a great chance to be approved in 2021 as the first disease-modifying drug in Alzheimer's Disease history. If that happens, then we likely will see $20 billion market cap instead of $1.56 billion market cap for this company, which implies stock price of around $540.


Reply
Westport Fuel - going to the moon
By: 
👤 yjaplomblazy guy 
đź’¬ 11
   Feb 06, 2021

$wprt - natural gas likely will be the leading renewable energy for next decade, and $wprt is a leader in natural gas, which can be generated from landfills, waste water plants. Amazon’s recent order likely to create additional demands for $wprt from other organizations. $wprt is also working with Scania on an injected hydrogen engine, which is another huge potential renewable energy market. This babe is on fire, and likely heading much higher.


Reply
Ocugen - a rocket ready to launch
By: 
👤 yjaplomblazy guy 
đź’¬ 11
   Feb 06, 2021

$ocgn has been focusing on developing transformative therapies to cure blindness disease, diabetic retinopathy, retinitis pigment is, and other rare genetic disorders. Now, it is partnering with Bahrat Biotech on COVID-19. This baby is absolutely on fire. $ocgn likely heading much higher.


Reply
TTOO - pandemic beneficiary
By: 
👤 yjaplomblazy guy 
đź’¬ 11
   Feb 05, 2021

$ttoo is a huge beneficiary of COVID-19 due to increased usage of its revolutionary diagnostic tools that resulted in 300% increase in its revenue. Furthermore, its enhanced reputation resulted from pandemic along with years’ of invested R&D will propel this one to grow healthily and steadily going forward.


Reply
Rocket Companies - to the moon
By: 
👤 yjaplomblazy guy 
đź’¬ 11
   Feb 05, 2021

$rkt is a high growth lender in the fintech sector with yoy quarterly revenue growth of 184.2%. Housing market is hot with all-time low interest rate. With job and economic recovery on the rise, more people will be able to work, earn better income, and afford to buy cars and houses. $rkt is also tapping to loans for car purchases. This one likely will surge soon.


Reply
$VIH - a premier crypto SPAC
By: 
👤 yjaplomblazy guy 
đź’¬ 11
   Feb 05, 2021

For those who invest it cryptos and SPACs, this gem and dynamite add excitement of both crypto and SPAC.

$VIH is in the process of acquiring Bakkt, a digital asset exchange platform backed by Intercontinental Exchange (ICE), Microsoft, and former Georgia senator Kelly Loeffler.

Digital asset is expected to see huge growth in coming years, and this will be a premier crypto exchange backed by strong industry leaders across tech and finance sectors.


Reply
GEVO - Bright path and huge market waiting to be tapped
By: 
👤 yjaplomblazy guy 
đź’¬ 11
   Jan 25, 2021

  1. GEVO's co-founder Frances Arnold - Nobel-Prize Winner has been named to President Joe Biden's Science Team;

  2. Gevo aims to transform renewable energy into low carbon transportation fuels. This next generation of renewable gasoline, jet fuel and diesel fuel has the potential to achieve zero carbon emissions, addressing the market need of reducing greenhouse gas emissions with sustainable alternatives.

  3. Gevo has benefited from Professor Arnold's work in developing enzymes to create technology that established GEVO as a leader in transforming renewable energy and carbo into energy dense liquids that have the potential to achieve a net-zero greenhouse footprint when used a drop-in fuels for transportation and other uses.

  4. Bill Gates, and the Bill and Melinda Gates Foundation are believers and supporters of Gevo's technology.

  5. In addition to addressing the problems of fuels, Gevo's technology also enables certain plastics, such as polyester, to be made with more sustainable ingredients. Gevo believes that its proven, patented, technology enabling the use of a variety of low-carbon sustainable feedstocks to produce price-competitive low carbon products such as gasoline components, jet fuel, and diesel fuel yields the potential to generate project and corporate returns that justify the build-out of a multi-billion-dollar business. Target price of $50 is reasonable.

https://i.imgur.com/ZP8tz42.jpg


Reply